Literature DB >> 18418051

p73-mediated transcriptional activity is negatively regulated by polo-like kinase 1.

Surinder M Soond1, Sean P Barry, Gerry Melino, Richard A Knight, David S Latchman, Anastasis Stephanou.   

Abstract

Trans-activating (TA) p73 is a member of the p53 family of transcription factors and has been implicated in cell cycle regulation, apoptosis and developmental processes. Although TAp73 positively regulates an overlapping repertoire of genes regulated by p53, TAp73 has been observed to be paradoxically overexpressed in a number of tumor cell types arousing much interest in the post-translational regulation of TAp73 transcriptional activity. Here, we present novel findings that show TAp73 can interact and co-localise, with Polo-Like Kinase 1 (PLK1) and that TAp73 is phosphorylated by this kinase on Threonine-27 (Thr-27) within the TA domain. Using reporter assays and Electrophoretic Mobility Shift Assays (EMSA), our findings suggest that TAp73-mediated activation of the p21(cip/waf), 14-3-3sigma and Bax gene promoters is abrogated by expressed PLK1 for which post-translational modification of TAp73 Thr-27 appears to be a key step in MCF7 cells. Thus highlighting a potential mechanism that uniquely contributes to PLK1-mediated and phosphor-dependent transcriptional deactivation of expressed TAp73.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18418051     DOI: 10.4161/cc.7.9.5777

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  13 in total

1.  Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain.

Authors:  Yongzhen Qian; Emily Hua; Kheem Bisht; Stephan Woditschka; Konstantine W Skordos; David J Liewehr; Seth M Steinberg; Edi Brogi; Muzaffar M Akram; J Keith Killian; Daniel C Edelman; Marbin Pineda; Stephanie Scurci; Yan Y Degenhardt; Sylvie Laquerre; Thomas A Lampkin; Paul S Meltzer; Kevin Camphausen; Patricia S Steeg; Diane Palmieri
Journal:  Clin Exp Metastasis       Date:  2011-09-21       Impact factor: 5.150

Review 2.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.

Authors:  Klaus Strebhardt
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

Review 3.  The role of aurora A and polo-like kinases in high-risk lymphomas.

Authors:  Carlos Murga-Zamalloa; Kedar V Inamdar; Ryan A Wilcox
Journal:  Blood Adv       Date:  2019-06-11

Review 4.  Polo-box domain: a versatile mediator of polo-like kinase function.

Authors:  Jung-Eun Park; Nak-Kyun Soung; Yoshikazu Johmura; Young H Kang; Chenzhong Liao; Kyung H Lee; Chi Hoon Park; Marc C Nicklaus; Kyung S Lee
Journal:  Cell Mol Life Sci       Date:  2010-02-11       Impact factor: 9.261

Review 5.  The p53 circuit board.

Authors:  Kelly D Sullivan; Corrie L Gallant-Behm; Ryan E Henry; Jean-Luc Fraikin; Joaquín M Espinosa
Journal:  Biochim Biophys Acta       Date:  2012-02-07

6.  CK2 phosphorylates and inhibits TAp73 tumor suppressor function to promote expression of cancer stem cell genes and phenotype in head and neck cancer.

Authors:  Hai Lu; Carol Yan; Xin Xin Quan; Xinping Yang; Jialing Zhang; Yansong Bian; Zhong Chen; Carter Van Waes
Journal:  Neoplasia       Date:  2014-10-23       Impact factor: 5.715

Review 7.  Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy.

Authors:  Frank Louwen; Juping Yuan
Journal:  Oncotarget       Date:  2013-07

8.  High expression of polo-like kinase 1 is associated with early development of hepatocellular carcinoma.

Authors:  Wei Sun; Qi Su; Xiankui Cao; Bin Shang; Aishan Chen; Hongzhuan Yin; Baolin Liu
Journal:  Int J Genomics       Date:  2014-06-11       Impact factor: 2.326

9.  Bioinformatics study of cancer-related mutations within p53 phosphorylation site motifs.

Authors:  Xiaona Ji; Qiang Huang; Long Yu; Ruth Nussinov; Buyong Ma
Journal:  Int J Mol Sci       Date:  2014-07-29       Impact factor: 5.923

10.  The F-box protein FBXO45 promotes the proteasome-dependent degradation of p73.

Authors:  A Peschiaroli; F Scialpi; F Bernassola; M Pagano; G Melino
Journal:  Oncogene       Date:  2009-07-06       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.